BeOne Medicines AG (ONC)
| Market Cap | 41.02B +13.3% |
| Revenue (ttm) | 6.13B +34.3% |
| Net Income | 655.71M |
| EPS | 5.59 |
| Shares Out | 113.70M |
| PE Ratio | 64.40 |
| Forward PE | 45.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,164 |
| Open | 362.51 |
| Previous Close | 359.97 |
| Day's Range | 358.51 - 365.00 |
| 52-Week Range | 253.95 - 385.22 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 432.80 (+19.97%) |
| Est. Earnings | Nov 5, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $432.8, which is an increase of 19.97% from the latest price.
News
BAKER BROS. ADVISORS LP Boosts BeOne Medicines Ltd (ONC) Stake -- Shares Look 5% Undervalued on ...
BAKER BROS. ADVISORS LP Boosts BeOne Medicines Ltd (ONC) Stake -- Shares Look 5% Undervalued on GF Value
BeOne Medicines AG at Morgan Stanley Global Healthcare Conference Transcript
BeOne Medicines AG at Morgan Stanley Global Healthcare Conference Transcript
BeOne Medicines AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into a global oncology leader with a robust pipeline, highlighted by pivotal solid tumor and hematology programs, strong commercial growth, and strategic partnerships. Financial guidance was raised on the back of BRUKINSA's performance, while ongoing innovation and global expansion remain priorities.
BeOne Medicines price target raised to $415 from $407 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $415 from $407 and keeps an Overweight rating on the shares after the FDA approved Ziihera and Tevimbra for…
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley ...
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
BeOne Medicines to expand access to cancer medicines under pact with U.S.
BeOne Medicines (ONC) announced a voluntary agreement with the U.S. Government to “expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprin...
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Gover...
BeOne Medicines announces new Phase 3 survival data on Ziihera
BeOne Medicines (ONC) announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera, in combination with chemotherapy, with and without Tev...
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second i...
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors? Let's find out.
BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA
BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of ...
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines renews partnerships to expand access to Brukinsa in leukemia
BeOne Medicines (ONC), together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a global health nonprofit organization, announced the renewal of their partne...
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundatio...
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.
BeOne Medicines price target raised to $370 from $340 at Wolfe Research
Wolfe Research analyst Kalpit Patel raised the firm’s price target on BeOne Medicines (ONC) to $370 from $340 and keeps an Outperform rating on the shares. BeOne’s $300M guidance increase…
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncolog...
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nas...
BeOne Medicines price target raised to $405 from $395 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $405 from $395 and keeps an Overweight rating on the shares. The company reported a beat-and-raise quarter, with…
BeOne Medicines price target raised to $454 from $424 at TD Cowen
TD Cowen analyst Yaton Werber raised the firm’s price target on BeOne Medicines (ONC) to $454 from $424 and keeps a Buy rating on the shares. The firm updated its…
BeOne Medicines price target raised to $418 from $416 at Truist
Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $418 from $416 and keeps a Buy rating on the shares. BeiGene delivered a strong Q2…
BeOne Medicines price target raised to $430 from $420 at Guggenheim
Guggenheim raised the firm’s price target on BeOne Medicines (ONC) to $430 from $420 and keeps a Buy rating on the shares following “positive” Q2 results, including a topline beat…
BeOne Medicines price target lowered to $450 from $451 at RBC Capital
RBC Capital lowered the firm’s price target on BeOne Medicines (ONC) to $450 from $451 and keeps an Outperform rating on the shares.
BeOne Medicines price target raised to $466 from $453 at Citi
Citi raised the firm’s price target on BeOne Medicines (ONC) to $466 from $453 and keeps a Buy rating on the shares. The firm views the Q2 report as strong.